Two Indian drugmakers seek to end trials of Merck's antiviral drug for moderate COVID-19

                             Two Indian drugmakers have requested permission to end late-stage trials of their generic versions of 

Merck

 NSE -0.09 % & Co's oral antiviral drug molnupiravir for moderate COVID-19, raising questions about how effective the experimental medicine is for that group of patients.

The Indian drug regulator's internal expert committee disclosed on its website that 

Aurobindo Pharma

 NSE .

Read more at: Click Here !